Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy Everest Medicines announced its interim results for the first half of 2025, revealing a significant 48% growth year-over-year driven by its innovative dual-engine strategy and key product advancements.

Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy #China #Shanghai #Everest_Medicines #NEFECON #VELSIPITY